<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280045</url>
  </required_header>
  <id_info>
    <org_study_id>FMRPUSP-UROGIN-001</org_study_id>
    <nct_id>NCT01280045</nct_id>
  </id_info>
  <brief_title>Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy</brief_title>
  <official_title>Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to assess if use of aromatase inhibitors could decrease volume of&#xD;
      uterine leiomyoma and cause same percentage of adverse effects during its use compared to&#xD;
      GnRH analogs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine leiomyoma is the most prevalent benign gynecologic tumor in women. Standard treatment&#xD;
      is surgical (hysterectomy or myomectomy), and depends of many variables. If these tumors are&#xD;
      large, preoperative assessment with clinical treatment may be useful in order to decrease its&#xD;
      volume, improve hematologic patterns and modify surgical approach (vaginal or abdominal). It&#xD;
      is well know that GnRH analogs can cause these goals; however, aromatase inhibitors are new&#xD;
      promising drugs which are being used for reducing uterine leiomyoma's volume and few&#xD;
      observational studies have shown this fact. The investigators are aiming to compare both&#xD;
      treatments in a randomized controlled trial and see if it both treatments are similar or not&#xD;
      in decreasing uterine leiomyoma's volume, influencing operative time, blood loss during&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No grant was received then we stopped the recruitment&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We woudl be comparing aromatase inhibitors versus GnRH analogs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Intra-operative time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine Leiomyoma Volume</measure>
    <time_frame>3 Months After Treatment, During Surgery</time_frame>
    <description>Volume measured by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>UTERINE LEIOMYOMA</condition>
  <arm_group>
    <arm_group_label>AROMATASE INHIBITOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this would be compared before and after VAGINAL HYSTERECTOMY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNRH ANALOG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this would be compared before and after VAGINAL HYSTERECTOMY</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VAGINAL HYSTERECTOMY</intervention_name>
    <description>GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS</description>
    <arm_group_label>AROMATASE INHIBITOR</arm_group_label>
    <arm_group_label>GNRH ANALOG</arm_group_label>
    <other_name>None declared</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  WOMEN OVER 40 YEARS, UTERINE VOLUME HIGHER THAN 300 ML, MINIMAL ANATOMIC CONDITIONS&#xD;
             FOR VAGINAL SURGERY&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ACTIVE GYNECOLOGIC MALIGNANCY&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <results_reference>
    <citation>Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010 Jan;93(1):192-8. doi: 10.1016/j.fertnstert.2008.09.064. Epub 2009 Jan 9.</citation>
    <PMID>19135657</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>LUIZ GUSTAVO OLIVEIRA BRITO</investigator_full_name>
    <investigator_title>Assistant Physician, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

